135 related articles for article (PubMed ID: 3541941)
1. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids.
Houghton JA; Williams LG; Dodge RK; George SL; Hazelton BJ; Houghton PJ
Biochem Pharmacol; 1987 Jan; 36(1):81-8. PubMed ID: 3541941
[TBL] [Abstract][Full Text] [Related]
2. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
Houghton JA; Williams LG; Torrance PM; Houghton PJ
Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
[TBL] [Abstract][Full Text] [Related]
3. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered beta-tubulins.
Houghton JA; Houghton PJ; Hazelton BJ; Douglass EC
Cancer Res; 1985 Jun; 45(6):2706-12. PubMed ID: 3986804
[TBL] [Abstract][Full Text] [Related]
4. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts.
Horton JK; Thimmaiah KN; Houghton JA; Horowitz ME; Houghton PJ
Biochem Pharmacol; 1989 Jun; 38(11):1727-36. PubMed ID: 2735930
[TBL] [Abstract][Full Text] [Related]
5. Stability of vincristine complexes in cytosols derived from xenografts of human rhabdomyosarcoma and normal tissues of the mouse.
Houghton JA; Williams LG; Houghton PJ
Cancer Res; 1985 Aug; 45(8):3761-7. PubMed ID: 2990677
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
Pierré A; Pérez V; Léonce S; Boutin JA; Saint-Dizier D; Hautefaye P; Lavielle G; Atassi G
Cancer Chemother Pharmacol; 1992; 29(5):367-74. PubMed ID: 1551175
[TBL] [Abstract][Full Text] [Related]
7. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
8. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts.
Horton JK; Houghton PJ; Houghton JA
Biochem Pharmacol; 1988 Oct; 37(20):3995-4000. PubMed ID: 3190743
[TBL] [Abstract][Full Text] [Related]
9. Uptake of Vinca alkaloids into mammalian nerve and its subcellular components.
Iqbal Z; Ochs S
J Neurochem; 1980 Jan; 34(1):59-68. PubMed ID: 6161213
[TBL] [Abstract][Full Text] [Related]
10. Altered molecular properties of tubulin in a multidrug-resistant variant of Chinese hamster cells selected for resistance to vinca alkaloids.
Pain J; Sirotnak FM; Barrueco JR; Yang CH; Biedler JL
J Cell Physiol; 1988 Aug; 136(2):341-7. PubMed ID: 3045133
[TBL] [Abstract][Full Text] [Related]
11. Influence of guanine nucleotides on vincristine binding in tumor cytosols and purified tubulin: evidence for an inhibitor of vincristine binding.
Bowman LC; Houghton JA; Houghton PJ
J Cell Physiol; 1990 Sep; 144(3):376-82. PubMed ID: 2391373
[TBL] [Abstract][Full Text] [Related]
12. Cellular uptake and tubulin binding properties of four Vinca alkaloids.
Singer WD; Himes RH
Biochem Pharmacol; 1992 Feb; 43(3):545-51. PubMed ID: 1540212
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
Horton JK; Houghton PJ; Houghton JA
Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
[TBL] [Abstract][Full Text] [Related]
14. GTP influences the binding of vincristine in human tumor cytosols.
Bowman LC; Houghton JA; Houghton PJ
Biochem Biophys Res Commun; 1986 Mar; 135(3):695-700. PubMed ID: 3964272
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate?
Houghton PJ; Houghton JA; Bowman LC; Hazelton BJ
Anticancer Drug Des; 1987 Oct; 2(2):165-79. PubMed ID: 3329524
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(1):45-52. PubMed ID: 7720175
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
[TBL] [Abstract][Full Text] [Related]
18. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
Kavallaris M; Tait AS; Walsh BJ; He L; Horwitz SB; Norris MD; Haber M
Cancer Res; 2001 Aug; 61(15):5803-9. PubMed ID: 11479219
[TBL] [Abstract][Full Text] [Related]
19. Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin.
Chi S; Xie W; Zhang J; Xu S
J Biomol Struct Dyn; 2015; 33(10):2234-54. PubMed ID: 25588192
[TBL] [Abstract][Full Text] [Related]
20. Studies with 4'-deoxyepivincristine (vinepidine), a semisynthetic vinca alkaloid.
Mullin K; Houghton PJ; Houghton JA; Horowitz ME
Biochem Pharmacol; 1985 Jun; 34(11):1975-9. PubMed ID: 4004913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
